欢迎访问上海俊喆生物技术公司官网!
咨询电话:13818676837 邮箱:501816433@qq.com
上海俊喆生物技术公司
Shanghai Junzhe Biotechnology Co., Ltd
  • 成功转染含有Mincle过表达质粒pcDNA3.1到骨髓源巨噬细胞(BMDM)发表文章已见刊

    Zeta Life转染试剂成功转染含有Mincle过表达质粒pcDNA3.1到骨髓源巨噬细胞(BMDM)西南医科大学,中西医结合研究中心科研工作者发表文章用Zeta Life Advanced DNA RNA,AD600150转染试剂成功转染含有Mincle过表达质粒pcDNA3.1到骨髓源巨噬细胞(BMDM),实验数据见下:. A&P inhibits the Mincle/Syk/NF-κB signaling pathway and M1 macrophage in vitro. The protein levels of each indicator in Western blot assay(A); The mRNA expression level of Mincle(B); The Flow results of Mincle, iNOS and CD206 in macrophages(C). *P < 0.05, **P < 0.01, ***P < 0.001 vs. LPS group; #P < 0.01 vs.Control group.用Zeta Life Advanced DNA RNA,AD600150转染试剂转染含有Mincle过表达质粒pcDNA3.1到骨髓源巨噬细胞(BMDM)的部分文章。
  • 浙江大学高效率转染质粒DNA、siRNA到免疫T(Vδ1 T)细胞,发表文章到nature-sigtrans

    一、浙江大学附属第二医院乳腺外科;浙江大学附属第二医院浙江省疗法肿瘤微环境与免疫重点实验室;浙江省人民医院,浙江省人民医院,杭州医学院附属人民医院,浙江省个体化医学肿瘤分子诊断与诊断重点实验室;绍兴大学附属医院甲状腺乳腺外科联合发表标题为Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+γδ1 Treg cells(乳腺癌衍生的外泌体传递lncRNA SNHG16诱导CD73 +γδ1 Treg细胞)的文章到nature.com/sigtrans,文章已被接受;二、本研究使用中使用Invigentech(英克)公司INVI DNA RNA 转染试剂转染质粒DNA、siRNA到Vδ1 T 免疫T细胞里面;三、本文中转染质粒DNA、siRNA,转染细胞数量信息如下:A. 将全长2435 bp的序列克隆到pCR3.1载体中构建SNHG16过表达载体;B. siRNA序列:SNHG16-homo-349,5′GCCUCUGCUGCUAAUUGUUTT-3'; SNHG16-homo-867, 5′-CCAAGGAGGGACUGUUUAATT-3′和SNHG16-homo-2004,5′-CCCAGUGUUGACUCACCAATT-3;C. 转染细胞用量:6孔板里面1 × 106 cells/well;四、发表文章部分内容如下:Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+γδ1 Treg cellsPlasmid construction and siRNA silencing A full-length 2435 bp sequence was cloned into the pCR3.1 vector toconstruct the SNHG16 overexpression vector. The sequences of SNHG16-specifific siRNAs were as follows: SNHG16-homo-349, 5′GCCUCUGCUGCUAAUUGUUTT-3′; SNHG16-homo-867, 5′-CCAAGGAGGGACUGUUUAATT-3′ and SNHG16-homo-2004, 5′-CCCAGUGUUGACUCACCAATT-3′. The miR-16–5p mimics, inhibitor and negativecontrols were purchased from GenePharma (SupplementaryTable S3).To manipulate the expression of miR-16–5p in Vδ1 T cells, Vδ1T cells were sorted from peripheral blood and seeded into six-wellplates at 1 × 106 cells/well with 1 ml of medium supplementedwith 10% FBS, 10 μg/ml CD3, 10 μg/ml CD28 and 40 U/mL IL-2.Then, transfection reagent (INVI DNA RNA Transfection Reagent,Invigentech, USA) and miR-16–5p mimics/NC/inhibitor/inhibitor NC (20 μm) were incubated with the cells for 48 h, after which the cells were collected for further experiments.but not Vδ2+ T cells were revealed to comprise the majority of TILs in all three BC molecular subtypes when gated on CD3 (p < 0.01, Fig. 1b, c). In addition, immunoflfluorescence of frozen sections further confifirmed the dominant distribution of Vδ1+T cells in BC (Fig. 1d). To further identify the function of breast cancer-infifiltrating γδ1T cells, BC cell lines (MCF-7, T-47D, MDA-MB-231 and MDA-MB-468) were co-cultured with freshly isolated Vδ1+ T cells frombreast tumour tissue (E:T ratios: 1:1, 5:1 and 10:1). Upon plotting the cell growth curve, the data show that γδ1 T cells did not exertinvigentech(英克)INVI DNA RNA转染试剂信息如下产品名称货号规格报价INVI DNA RNA 转染试剂IV12160250.25 ml询价INVI DNA RNA 转染试剂IV12160500.50 ml询价INVI DNA RNA 转染试剂IV12160750.75 ml询价INVI DNA RNA 转染试剂IV12161001.00 ml询价INVI DNA RNA 转染试剂IV12161501.50 ml询价INVI DNA RNA 转染试剂IV12163003.00 ml询价www.ivigt.com
  • 转染原代破骨细胞前体细胞,在已发表期刊文章中使用invigentech转染试剂的转染经验分享

    西部战区总医院药学部,在2021年发表文章到Cell Communication and Signaling的学术期刊中科研者使用美国invigentech转染试剂,高效率转染原代破骨细胞前体细胞(Osteoclast precursor cells),具体转染原代破骨细胞前体细胞方法经验如下:(注意:本文转染实验中使用的细胞数量、试剂用量和操作方法不适用于传统lipo3000转染试剂或类似产品)。Cell cultureSorted primary CD115(+) precursors were cultured in α-minimal essential medium (MEM) containing 10% FBS,1% penicillin-streptomycin solution and 50 ng ml− 1 colony stimulating factor (M-CSF, Abcam). After 3 days,the medium was replaced with fresh medium. LA was added at a concentration of 100 μg/ml to stimulate the precursors. To inhibit the expression of Cadherin-11, the primary osteoclast precursors were transfected with Cadherin-11 siRNA using INVI DNA RNA Transfection reagent (Invigentech) for 24 h. The sequence of Cadherin-11 siRNA was CCAATGGACCAAGATTTAT. In some experiments, primary cells were treated with BYL719 (2.5 μM), GSK690693 (25 nM), 666–15 (50 nM), rapamycin (20 μM), or AMG-487 (30 μM).Invigentech.英克: 简介美国 Invigentech(英克)公司是开发用于细胞培养的胎牛血清、细胞活力检测、细胞筛选、细胞支原体清除、细胞转染和组织再生的新型血清替代品全球***之一;提供inviCELL™Platelet lysate无动物血清产品用于支持广泛的细胞扩增和生产,包括培养间充质干细胞和多种免疫细胞系等,为制药公司或者生物技术公司提供无血清细胞培养规模生产服务;INVI DNA  RNA Transfection Reagent为原代细胞、悬浮细胞、小动物活体转染提供高品质转染试剂;此外我们引进的新设施可生产高纯度注射用水和生物处理解决方案,用于满足任何细胞、科研和企业客户需求,保证每个指定批次胎牛血清、细胞活力检测、细胞筛选细胞,转染等产品质量的稳定性,以加速安全有效的基于细胞和组织的治疗研究、开发和商业化。www.ivigt.com
  • 转染BMMs细胞,在已发表Portland Press期刊文章中使用invigentech转染试剂的转染经验分享

    一、西南交通大学医学院发表标题为:Colorectal cancer cells promote osteoclastogenesis and bone destruction through regulating EGF/ERK/CCL3 pathway的文章到Portland Press;二、A.用invigentech(英克)INVI DNA RNA Transfection Reagent转染试剂; B.A6906FBS-500,FBS Ultra-low Endotoxin胎牛血清对BMMs细胞(骨髓单核巨噬细胞)进行培养;三、成功转染BMMs细胞(骨髓单核巨噬细胞)发表文章已见刊;四、文章简介:大肠癌细胞通过调节来促进破骨细胞生成和骨破坏EGF / ERK / CCL3途径.五、文章部分内容见下:Cell isolation, culture, and treatmentInvigentech.英克: 简介美国 Invigentech(英克)公司是开发用于细胞培养的胎牛血清、细胞活力检测、细胞筛选、细胞支原体清除、细胞转染和组织再生的新型血清替代品全球***之一;提供inviCELL™Platelet lysate无动物血清产品用于支持广泛的细胞扩增和生产,包括培养间充质干细胞和多种免疫细胞系等,为制药公司或者生物技术公司提供无血清细胞培养规模生产服务;INVI DNA  RNA Transfection Reagent为原代细胞、悬浮细胞、小动物活体转染提供高品质转染试剂;此外我们引进的新设施可生产高纯度注射用水和生物处理解决方案,用于满足任何细胞、科研和企业客户需求,保证每个指定批次胎牛血清、细胞活力检测、细胞筛选细胞,转染等产品质量的稳定性,以加速安全有效的基于细胞和组织的治疗研究、开发和商业化。www.ivigt.com
  • 四川大学胃肠癌中心国家重点实验室成功转染DC2.4细胞(小鼠骨髓来源树突状细胞)发表文章已经见刊

    喜讯 四川大学胃肠癌中心国家重点实验室用美国invigentech(英克)公司  INVI DNA RNA Transfection Reagent转染试剂 成功转染DC2.4细胞(小鼠骨髓来源树突状细胞)发表文章已经见刊。
Copyright © 2022 上海俊喆生物技术公司 All Rights Reserved.